CRISPR Firm Intellia Prices IPO at $16 to $18 Per Share

Apr 27, 2016

|

NEW YORK (GenomeWeb) – Intellia Therapeutics has priced shares for its upcoming initial public offering in the range of $16 to $18, according to an amendment to its preliminary prospectus filed today with the US Securities and Exchange Commission.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Refined Risk Prediction

Researchers are refining a tool to predict a woman's risk of developing breast cancer, according to the Guardian.

Shutdown and the FDA

According to Stat News, the partial government shutdown in the US could soon affect the ability of the Food and Drug Administration to review new drugs.

This Week in PNAS

In PNAS this week: gypsy moth genome sequenced, phylogenomic analysis of Polyneopterans, and more.

Influences from Here and There

CNN reports that people's genes tend to have a greater influence on their risk of developing disease than their environment, but it varies by phenotype.

Featured White Papers

Controlling Ribonuclease (RNase) with High Irradiance UV LED Light Engines

The Ultimate Guide to Mouse Clinical Trials

High Throughput RT-qPCR for Gene Expression Analysis

Feb

21

Featured Webinar

Case Study: 'Companion Informatics' to Automate Immunotherapy Manufacturing and Treatment

This webinar will provide a first-hand look at how Gradalis, a clinical-stage immunotherapy developer, is using an information management solution from L7 to streamline its research, clinical, and manufacturing operations.

Main menu